English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Neuroprostanes, a family of non-enzymatic metabolites of the docosahexaenoic acid, have been suggested as potential biomarkers for neurological diseases. Objective biological markers are strongly needed in Rett syndrome (RTT), which is a progressive X-linked neurodevelopmental disorder that is mainly caused by mutations in the methyl-CpG binding protein 2 ( MECP2 ) gene with a predominant multisystemic phenotype. The aim of the study is to assess a possible association between  MECP2  mutations or RTT disease progression and plasma levels of 4( RS )-4-F 4t -neuroprostane (4-F 4t -NeuroP) and 10( RS )-10-F 4t -neuroprostane (10-F 4t -NeuroP) in typical RTT patients with proven  MECP2  gene mutation. Clinical severity and disease progression were assessed using the Rett clinical severity scale (RCSS) in n = 77 RTT patients. The 4-F 4t -NeuroP and 10-F 4t -NeuroP molecules were totally synthesized and used to identify the contents of the plasma of the patients. Neuroprostane levels were related to  MECP2  mutation category (i.e., early truncating, gene deletion, late truncating, and missense), specific hotspot mutations (i.e., R106W, R133C, R168X, R255X, R270X, R294X, R306C, and T158M), and disease stage (II through IV). Circulating 4-F 4t -NeuroP and 10-F 4t -NeuroP were significantly related to (i) the type of  MECP2  mutations where higher levels were associated to gene deletions ( p  ≤ 0.001); (ii) severity of common hotspot  MECP2  mutation (large deletions, R168X, R255X, and R270X); (iii) disease stage, where higher concentrations were observed at stage II ( p  ≤ 0.002); and (iv) deficiency in walking ( p  ≤ 0.0003). This study indicates the biological significance of 4-F 4t -NeuroP and 10-F 4t -NeuroP as promising molecules to mark the disease progression and potentially gauge genotype–phenotype associations in RTT.

Circulating 4-F4t-Neuroprostane and 10-F4t-Neuroprostane Are Related to MECP2 Gene Mutation and Natural History in Rett Syndrome